Literature DB >> 21178509

Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone.

Shuhong Liu1, Maisa Yoshimoto, Kiril Trpkov, Qiuli Duan, Matthew Firszt, Jacques Corcos, Jeremy A Squire, Tarek A Bismar.   

Abstract

To assess the incidence of ERG rearrangements and PTEN deletions in a group of prognostically favorable PCA tumors of the transition zone (TZ). We interrogated 54 unsuspected PCA tumors using fluorescence in-situ hybridization for ERG rearrangements and PTEN deletions. ERG rearrangements were detected in 6/47 (12.7%) cases with 4/6 (66%) occurring by deletion. PTEN deletions were detected in 9/47 (19.1%) cases with only 3/47 (6.4%) having both PTEN losses and ERG rearrangements (p = 0.07). Only ERG rearrangements were associated with higher tumor volume > 5% (p = 0.04); PTEN deletions showed similar trends (p = 0.06). None of the markers showed association with Gleason score. In conclusion, although TZ and peripheral zone tumors share similar molecular etiologies, they exhibit differences in the rates of ERG and PTEN aberrations. The differences of ERG and /or PTEN genetic aberrations in TZ tumors may point toward a subset of tumors with adverse behavior. Additional studies implementing ERG and PTEN tissue-based FISH assays in tumors of the TZ are warranted to substantiate the potential clinical value of these biomarkers in the management of men with incidental PCA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21178509     DOI: 10.4161/cbt.11.6.14376

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  16 in total

1.  High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.

Authors:  Adrian Box; Mohammed Alshalalfa; Samar A Hegazy; Bryan Donnelly; Tarek A Bismar
Journal:  Tumour Biol       Date:  2016-06-07

2.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

3.  The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Authors:  Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

4.  Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.

Authors:  Antoun Toubaji; Roula Albadine; Alan K Meeker; William B Isaacs; Tamara Lotan; Michael C Haffner; Alcides Chaux; Jonathan I Epstein; Misop Han; Patrick C Walsh; Alan W Partin; Angelo M De Marzo; Elizabeth A Platz; George J Netto
Journal:  Mod Pathol       Date:  2011-07-08       Impact factor: 7.842

Review 5.  ERG expression in prostate cancer: biological relevance and clinical implication.

Authors:  Hatem Abou-Ouf; Liena Zhao; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-28       Impact factor: 4.553

Review 6.  Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Med       Date:  2011-05-20       Impact factor: 6.354

7.  ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.

Authors:  K-C Huang; M Dolph; B Donnelly; T A Bismar
Journal:  Clin Transl Oncol       Date:  2014-05-06       Impact factor: 3.405

8.  TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.

Authors:  Anuradha Gopalan; Margaret A Leversha; Maria E Dudas; Alexandra C Maschino; Jeremy Chang; Hikmat A Al-Ahmadie; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter; Samson W Fine
Journal:  Histopathology       Date:  2013-05-23       Impact factor: 5.087

9.  Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment.

Authors:  Jacqueline Fontugne; Daniel Lee; Chiara Cantaloni; Christopher E Barbieri; Orazio Caffo; Esther Hanspeter; Guido Mazzoleni; Paolo Dalla Palma; Mark A Rubin; Giovanni Fellin; Juan Miguel Mosquera; Mattia Barbareschi; Francesca Demichelis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-10       Impact factor: 4.254

10.  Eupafolin suppresses prostate cancer by targeting phosphatidylinositol 3-kinase-mediated Akt signaling.

Authors:  Kangdong Liu; Chanmi Park; Hanyong Chen; Joonsung Hwang; N R Thimmegowda; Eun Young Bae; Ki Won Lee; Hong-Gyum Kim; Haidan Liu; Nak Kyun Soung; Cong Peng; Jae Hyuk Jang; Kyoon Eon Kim; Jong Seog Ahn; Ann M Bode; Ziming Dong; Bo Yeon Kim; Zigang Dong
Journal:  Mol Carcinog       Date:  2014-04-04       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.